Ocular Therapeutix (OCUL) PT Raised to $11 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ocular Therapeutix (OCUL) PT Raised to $24 at Cantor Fitzgerald on DEXTENZA Approval
December 3, 2018 9:42 AM ESTCantor Fitzgerald analyst Elemer Piros raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $24.00 (from $22.00) while maintaining an Overweight rating following the DEXTENZA approval.
Piros commented, "This morning Ocular Therapeutix held a conference call and announced that DEXTENZA 0.4mg... More
Pre-Open Movers 12/03: (TSRO) (GBT) (NBEV) Higher; (OCUL) (BLUE) (GSK) Lower (more...)
December 3, 2018 9:25 AM ESTPre-Open Movers
TESARO Inc (NASDAQ: TSRO) 59% HIGHER; GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). The proposed transaction significantly strengthens GSKs pharmaceutical business, accelerating the build of GSKs pipeline and commercial capability in oncology.
Ocular Therapeutix (OCUL) to Resume Trading at 7:30 am ET
December 3, 2018 7:19 AM ESTOcular Therapeutix (NASDAQ: OCUL) to Resume Trading at 7:30 am ET
... MoreOcular Therapeutix (OCUL) Announces FDA Approval of DEXTENZA for Treatment of Ocular Pain
December 3, 2018 7:01 AM ESTOcular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use for the treatment of ocular pain following ophthalmic surgery.
We are extremely pleased to announce the approval of DEXTENZA, coming so soon after our pre-approval inspection and... More
